VYNE Therapeutics Inc
Research VYNE Therapeutics Inc (VYNE) on Bullrun: market cap USD 952.56M, dividend yield 140.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVYNE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 952.56M
- Dividend yield140.2%
- Financial periodQ1 2026
- RevenueUSD 86.00K
- Net income-USD 3.59M
- Free cash flow-USD 4.08M
Valuation Snapshot
latest market cap is USD 952.56M; dividend yield is 140.2%.
Peer valuation comparison
Latest dividend yield is 140.24% versus a Healthcare sector median of 1.81% (7648.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 570.00K | -USD 26.48M | -USD 33.12M | n/a | -0.62 | USD 24.03M | USD 0 | USD 27.77M |
| FY2024 | USD 501.00K | -USD 39.83M | -USD 34.09M | n/a | -0.93 | USD 19.93M | USD 0 | USD 52.09M |
| FY2023 | USD 424.00K | -USD 28.45M | -USD 25.34M | n/a | -2.78 | USD 30.62M | USD 0 | USD 88.74M |
| FY2022 | USD 477.00K | -USD 23.21M | -USD 29.20M | n/a | -7.28 | USD 30.91M | USD 0 | USD 31.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-27 | USD 952.56M | n/a | 140.8% | 40.22 |
| 2025 | 2025-12-31 | USD 19.33M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 49.68M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 32.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.71M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 54.65M | n/a | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 40.22 USD, yield 140.2%.
About VYNE Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VYNE Therapeutics Inc's market cap?
VYNE Therapeutics Inc's market capitalization is USD 952.56M.
Does VYNE Therapeutics Inc pay a dividend?
VYNE Therapeutics Inc has a dividend yield of 140.2%.
What does VYNE Therapeutics Inc do?
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure.